» Articles » PMID: 39201382

Studying Pathogenetic Contribution of a Variant of Unknown Significance, P.M659I (c.1977G > A) in MYH7, to the Development of Hypertrophic Cardiomyopathy Using CRISPR/Cas9-Engineered Isogenic Induced Pluripotent Stem Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Aug 29
PMID 39201382
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertrophic cardiomyopathy (HCM) is a cardiovascular pathology that is caused by variants in genes encoding sarcomere-associated proteins. However, the clinical significance of numerous variants in HCM-associated genes is still unknown. CRISPR/Cas9 is a tool of nucleotide sequence editing that allows for the unraveling of different biological tasks. In this study, introducing a mutation with CRISPR/Cas9 into induced pluripotent stem cells (iPSCs) of a healthy donor and the directed differentiation of the isogenic iPSC lines into cardiomyocytes were used to assess the pathogenicity of a variant of unknown significance, p.M659I (c.1977G > A) in , which was found previously in an HCM patient. Using two single-stranded donor oligonucleotides with and without the p.M659I (c.1977G > A) mutation, together with CRISPR/Cas9, an iPSC line heterozygous at the p.M659I (c.1977G > A) variant in was generated. No CRISPR/Cas9 off-target activity was observed. The iPSC line with the introduced p.M659I (c.1977G > A) mutation in retained its pluripotent state and normal karyotype. Compared to the isogenic control, cardiomyocytes derived from the iPSCs with the introduced p.M659I (c.1977G > A) mutation in recapitulated known HCM features: enlarged size, elevated diastolic calcium level, changes in the expression of HCM-related genes, and disrupted energy metabolism. These findings indicate the pathogenicity of the variant.

Citing Articles

Advances in Pathophysiological Mechanisms of Degenerative Aortic Valve Disease.

Yu Y, Jiang Q Cardiol Res. 2025; 16(2):86-101.

PMID: 40051666 PMC: 11882237. DOI: 10.14740/cr2012.


Generation of Isogenic iPSC Lines for Studying the Effect of the p.N515del (c.1543_1545delAAC) Variant on MYBPC3 Function and Hypertrophic Cardiomyopathy Pathogenesis.

Pavlova S, Shulgina A, Minina J, Zakian S, Dementyeva E Int J Mol Sci. 2024; 25(23).

PMID: 39684611 PMC: 11641397. DOI: 10.3390/ijms252312900.

References
1.
Ramachandra C, Mai Ja K, Lin Y, Shim W, Boisvert W, Hausenloy D . INDUCED PLURIPOTENT STEM CELLS FOR MODELLING ENERGETIC ALTERATIONS IN HYPERTROPHIC CARDIOMYOPATHY. Cond Med. 2020; 2(4):142-151. PMC: 7250397. View

2.
Vander Roest A, Liu C, Morck M, Kooiker K, Jung G, Song D . Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state. Proc Natl Acad Sci U S A. 2021; 118(24). PMC: 8214707. DOI: 10.1073/pnas.2025030118. View

3.
Wang L, Kim K, Parikh S, Cadar A, Bersell K, He H . Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes. J Mol Cell Cardiol. 2017; 114:320-327. PMC: 5800960. DOI: 10.1016/j.yjmcc.2017.12.002. View

4.
Mosqueira D, Mannhardt I, Bhagwan J, Lis-Slimak K, Katili P, Scott E . CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. Eur Heart J. 2018; 39(43):3879-3892. PMC: 6234851. DOI: 10.1093/eurheartj/ehy249. View

5.
Tanosaki S, Tohyama S, Kishino Y, Fujita J, Fukuda K . Metabolism of human pluripotent stem cells and differentiated cells for regenerative therapy: a focus on cardiomyocytes. Inflamm Regen. 2021; 41(1):5. PMC: 7852150. DOI: 10.1186/s41232-021-00156-9. View